Health Care · Services-Offices & Clinics of Doctors of Medicine · NYSE · CIK 1773751 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $25.00Day −14.73%Mkt cap $6.5BP/E (FY) 49.0×1Y −58.5%Off 52W high −64.5%Vol (1Y) 92.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest23.8% of sh out |
| Days to cover4.5d |
| 13F net flow (QoQ)−9.89% |
| Top-10 13F concentration59.3% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)49.0× |
| Sales (TTM)$2.37B |
| Earnings (TTM)-$13.2M |
| ROE25.2% |
| Net margin5.5% |
| ROIC37.2% |
| Sales growth 3Y64.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−23.0% |
| 1Y−58.5% |
| 3Y+178.7% |
| 5Y+215.3% |
| Since incept. (ann.)+6.5% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.4% |
| Ann. volatility (3Y)93.8% |
| Sharpe (1Y)−0.50 |
| Sharpe (3Y)0.85 |
| Max drawdown (1Y)−78.1% |
| Max drawdown (3Y)−78.9% |
| Beta (3Y vs SPY)4.29 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 26.3M | $547M | 10.20% | −0.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.2M | $211M | 3.94% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.3M | $194M | 3.62% | new |
| MORGAN STANLEY | 8.9M | $185M | 3.44% | +126.2% |
| STATE STREET CORP | 7.5M | $155M | 2.89% | +2.1% |
| Defiance ETFs, LLC | 7.4M | $154M | 2.88% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 5.2M | $108M | 2.01% | −5.6% |
| JPMORGAN CHASE & CO | 5.2M | $98M | 2.03% | −72.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.40 | −300.0% | $608.1M | +3.8% |
| 2025-12-31 | 2026-02-23 | — | — | $617.8M | +28.4% |
| 2025-09-30 | 2025-11-03 | $0.06 | −81.3% | $599.0M | +49.2% |
| 2025-06-30 | 2025-08-04 | $0.17 | +183.3% | $544.8M | +72.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 94% · Non Us 6%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
